Justin Eyquem, PhD
Assistant Professor, Dept. of Medicine, UCSF
Research Summary
I received my PhD from the University of Paris-Diderot in collaboration with the biotech company Cellectis. During my PhD, I participated to the development of gene editing tools such as Meganuclease or TALEN in primary human cells and notably identified genomic location for safe integration of therapeutic genes. In 2014, I joined Michel Sadelain's lab at the MSKCC and used CRISPR/Cas9 to engineer CAR T cells. I showed how targeting CAR transgene into specific loci enhance T cell efficacy, advance CAR immuno-biology and facilitate T cell manufacturing. Early 2019, I received the Parker Fellow Award and opened my lab in the department of Microbiology and Immunology at UCSF where I am developing a gene editing platform to enhance CAR T and NK cell functions in hematological and solid tumors.
Education
University of Bordeaux, France, B.S., 2006, Biology/Chemistry
AgroParisTech, France, Master, 2010, Bioengineering
University of Paris VII, France, Master, 2010, Genetics
University of Paris VII, France, Ph.D., 2014, Immunology - Molecular Biology
Memorial Sloan-Kettering Cancer Center, Postdoctoral, 2019, Immunotherapy
Honors & Awards
- 2017
Best publication of the year - Cornell/MSKCC Immunology and Microbial Pathogenesis; Eyquem et al. Nature 2017 - 2018
Parker Fellow Award 2018
Selected Publications
- Hamieh M, Dobrin A, Cabriolu A, van der Stegen SJC, Giavridis T, Mansilla-Soto J,Eyquem J, Zhao Z, Whitlock BM, Miele MM, Li Z, Cunanan KM, Huse M, HendricksonRC, Wang X, Riviere I, Sadelain M. CAR T cell trogocytosis and cooperativekilling regulate tumour antigen escape. Nature. 2019 Apr;568(7750):112-116.
View on PubMed - Feucht J, Sun J, Eyquem J, Ho YJ, Zhao Z, Leibold J, Dobrin A, Cabriolu A, HamiehM, Sadelain M. Calibration of CAR activation potential directs alternative T cellfates and therapeutic potency. Nat Med. 2019 Jan;25(1):82-88.
View on PubMed - DeSelm C, Palomba ML, Yahalom J, Hamieh M, Eyquem J, Rajasekhar VK, Sadelain M.Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape.Mol Ther. 2018 Nov 7;26(11):2542-2552.
View on PubMed - Krebs S, Ahad A, Carter LM, Eyquem J, Brand C, Bell M, Ponomarev V, Reiner T,Meares CF, Gottschalk S, Sadelain M, Larson SM, Weber WA. Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes. J Nucl Med. 2018 Dec;59(12):1894-1900.
View on PubMed - Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M.CAR T cell-induced cytokine release syndrome is mediated by macrophages andabated by IL-1 blockade. Nat Med. 2018 Jun;24(6):731-738.
View on PubMed - Perna F, Berman SH, Soni RK, Mansilla-Soto J, Eyquem J, Hamieh M, Hendrickson RC,Brennan CW, Sadelain M. Integrating Proteomics and Transcriptomics for SystematicCombinatorial Chimeric Antigen Receptor Therapy of AML. Cancer Cell. 2017 Oct9;32(4):506-519.e5.
View on PubMed - Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJ, Hamieh M, Cunanan KM, Odak A, Gonen M, Sadelain M. Targeting a CAR to the TRAC locus with CRISPR/Cas9enhances tumour rejection. Nature. 2017 Mar 2;543(7643):113-117.
View on PubMed - Poirot L, Philip B, Schiffer-Mannioui C, Le Clerre D, Chion-Sotinel I, DerniameS, Potrel P, Bas C, Lemaire L, Galetto R, Lebuhotel C, Eyquem J, Cheung GW,Duclert A, Gouble A, Arnould S, Peggs K, Pule M, Scharenberg AM, Smith J.Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf"Adoptive T-cell Immunotherapies. Cancer Res. 2015 Sep 15;75(18):3853-64.
View on PubMed - Duportet X, Wroblewska L, Guye P, Li Y, Eyquem J, Rieders J, Rimchala T, Batt G, Weiss R. A platform for rapid prototyping of synthetic gene networks in mammaliancells. Nucleic Acids Res. 2014 Dec 1;42(21):13440-51.
View on PubMed - Eyquem J, Poirot L, Galetto R, Scharenberg AM, Smith J. Characterization of threeloci for homologous gene targeting and transgene expression. Biotechnol Bioeng. 2013 Aug;110(8):2225-35.
View on PubMed